Rule, S A, Savage, D G, O'Brien, S G, Orchard, K, McDonald, C, Davidson, J, Matthey, F, Reilly, J T, Bardhan, G, Miller, E, Cranfield, T, Apperley, J F and Goldman, J M (1996) Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia. British Journal of Haematology, 94 (4), 694-8.
Abstract
Between June 1994 and October 1995 we performed 11 autografts in nine patients with advanced-phase chronic myeloid leukaemia (CML) using an attenuated cytoreductive regimen consisting of busulphan 8 mg/kg given in divided doses over 4 d. Five patients were restored to chronic phase. Four patients survived > 50 weeks and one remains well at 79 weeks. Toxicity was generally mild. Four procedures were managed entirely in the out-patient clinic. Therefore autografting after this 'intermediate' dose busulphan provides good palliation for patients with advanced CML with relatively little toxicity. Attenuated autografting should offer major advantages in terms of quality of life and cost for patients with advanced-phase CML.
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.